Johnson & Johnson (NYSE:JNJ) Shares Sold by Papp L Roy & Associates
Johnson & Johnson (NYSE:JNJ) Shares Sold by Papp L Roy & Associates
Papp L Roy & Associates lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 112,873 shares of the company's stock after selling 3,908 shares during the quarter. Johnson & Johnson makes up 2.8% of Papp L Roy & Associates' holdings, making the stock its 8th biggest holding. Papp L Roy & Associates' holdings in Johnson & Johnson were worth $19,939,000 as of its most recent filing with the SEC.
Other hedge funds have also recently made changes to their positions in the company. DORCHESTER WEALTH MANAGEMENT Co raised its position in Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company's stock valued at $14,975,000 after buying an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P lifted its position in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company's stock valued at $31,049,000 after purchasing an additional 82,429 shares in the last quarter. AMI Investment Management Inc. boosted its holdings in Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company's stock worth $3,244,000 after purchasing an additional 1,475 shares during the last quarter. Equitable Holdings Inc. grew its position in Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company's stock worth $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd increased its stake in Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company's stock valued at $152,488,000 after buying an additional 20,528 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.
Get Johnson & Johnson alerts:
Analyst Upgrades and Downgrades
JNJ has been the topic of a number of recent analyst reports. Citigroup lifted their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a "buy" rating in a research note on Monday, December 12th. SVB Leerink lowered their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating on the stock in a research report on Friday, January 20th. Atlantic Securities increased their target price on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a "neutral" rating in a research report on Wednesday, January 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. Finally, StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday, March 16th. They set a "strong-buy" rating for the company. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $174.73.
Insider Buying and Selling at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.35% of the stock is owned by company insiders.
Johnson & Johnson Stock Up 1.0 %
NYSE:JNJ opened at $152.65 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The firm's 50-day moving average price is $159.76 and its 200-day moving average price is $167.55. The company has a market capitalization of $397.54 billion, a PE ratio of 22.65, a P/E/G ratio of 2.60 and a beta of 0.54. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts' consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter last year, the firm earned $2.13 earnings per share. The business's revenue for the quarter was down 4.4% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.5 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson's dividend payout ratio (DPR) is 67.06%.
Johnson & Johnson Company Profile
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.
Further Reading
Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
MarketBeat Week in Review – 3/20 – 3/24
Dividend King Genuine Parts Company Upgraded On Profit Guidance
The Bottom Is In For Accenture
11 Best Consumer Discretionary Stocks of 2023
10 Best Consumer Discretionary ETFs
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
據Papp L Roy & Associates公司在最近向美國證券交易委員會披露的信息,該公司在第四季度減少了其在強生(NYSE:JNJ)的股份3.3%。該基金在本季度出售了3,908股股票後,擁有該公司112,873股股票。強生佔Papp L Roy & Associates持股量的2.8%,使該股成爲第八大持股。截至最近向美國證券交易委員會提交文件時,Papp L Roy & Associates在強生公司的股份價值19,939,000美元。
其他對沖基金最近也調整了在該公司的頭寸。多切斯特財富管理公司在第一季度將其在強生公司的頭寸提高了8.6%。多切斯特財富管理公司在上個季度又購買了5,327股股票後,現在擁有該公司67,618股股票,價值14,975,000美元。坎託·菲茨傑拉德投資顧問有限責任公司在第一季度將其在強生公司股票中的頭寸提高了88.9%。坎託·菲茨傑拉德投資顧問有限責任公司在上個季度又購買了82,429股股票後,現在擁有該公司175,194股股票,價值31,049,000美元。AMI投資管理公司在第一季度將其在強生公司的持股量增加了8.8%。AMI Investment Management Inc.在上個季度又購買了1,475股股票後,現在擁有該公司18,305股股票,價值324.4萬美元。Equity Holdings Inc.在第一季度,其在強生公司的頭寸增長了4.9%。Equity Holdings Inc.在上個季度又購買了2,119股股票後,現在擁有該公司45,673股股票,價值8,095,000美元。最後,USS Investment Management Ltd在第一季度將其在強生公司的股份增加了2.4%。USS Investment Management Ltd在上個季度又購買了20,528股股票後,現在擁有該公司860,371股股票,價值152,488,000美元。該股票的67.94%由機構投資者和對沖基金持有。
得到 強生公司 警報:
分析師升級和降級
JNJ一直是最近多份分析師報告的話題。花旗集團在12月12日星期一的一份研究報告中將強生公司的目標價格從198.00美元上調至205.00美元,並將該股評爲 “買入”。SVB Leerink在1月20日星期五的一份研究報告中將強生公司股票的目標價格從194.00美元下調至186.00美元,並對該股設定了 “跑贏大盤” 的評級。大西洋證券在1月25日星期三的一份研究報告中將強生公司股票的目標價格從160.00美元上調至168.00美元,並將該公司評爲 “中性”。坎託·菲茨傑拉德在2月1日星期三的一份報告中重申了 “增持” 評級,並對強生公司的股票發佈了215.00美元的目標股價。最後,StockNews.com在3月16日星期四的一份報告中開始報道強生公司。他們爲該公司設定了 “強勢買入” 評級。七位投資分析師對該股進行了持有評級,六位給出了買入評級,一位對該公司股票給出了強勁的買入評級。根據Marketbeat.com的數據,該公司目前的平均評級爲 “適度買入”,共識目標價爲174.73美元。
強生公司的內幕買入和賣出
在其他新聞方面,內部人士詹姆斯·斯旺森在3月6日星期一進行的一筆交易中出售了1,062股股票。這些股票的平均價格爲154.66美元,總交易額爲164,248.92美元。出售後,該內部人士現在擁有該公司的9,215股股份,價值1425,191.90美元。該交易是在向美國證券交易委員會提交的文件中披露的,該文件可在 這個鏈接。0.35%的股票由公司內部人士擁有。
強生公司股票上漲 1.0%
紐約證券交易所代碼:JNJ週五開盤價爲152.65美元。該公司的債務與權益比率爲0.35,流動比率爲0.99,速動比率爲0.77。該公司的50天移動平均線價格爲159.76美元,其200天移動平均線價格爲167.55美元。該公司的市值爲3975.4億美元,市盈率爲22.65,市盈率爲2.60,beta爲0.54。強生公司創下1年低點150.11美元,1年高點186.69美元。
強生(紐約證券交易所代碼:JNJ — Get Rating)上次公佈財報是在1月24日星期二。該公司公佈了本季度每股收益2.35美元,比分析師普遍預期的2.22美元高出0.13美元。強生公司的淨利潤率爲18.90%,股本回報率爲35.76%。該業務在本季度的收入爲237.1億美元,而市場普遍預期爲239.0億美元。去年同期,該公司的每股收益爲2.13美元。該業務本季度的收入同比下降4.4%。股票分析師平均預測,強生將在本財年公佈每股收益10.5%。
強生分紅公告
該公司最近還披露了季度股息,該股息已於3月7日星期二支付。2月21日星期二登記在冊的投資者獲得了每股1.13美元的股息。這意味着年化股息爲4.52美元,收益率爲2.96%。本次股息的除息日爲2月17日星期五。強生公司的股息支付率(DPR)爲67.06%。
強生公司簡介
(獲取評級)
強生是一家控股公司,從事醫療保健領域產品的研發、製造和銷售。它通過以下部門運營:消費者健康、製藥和醫療技術。消費者健康板塊包括專注於皮膚健康/美容、非處方藥、嬰兒護理、口腔護理、女性健康和傷口護理市場中使用的個人醫療保健的產品。
進一步閱讀
免費獲取 StockNews.com 關於強生公司(JNJ)的研究報告
MarketBeat Week 回顧 — 3 月 20 日 — 3 月 24 日
Diversion King 原裝零件公司在利潤指導上
埃森哲已經觸底了
2023 年 11 只最佳非必需消費品股
十大最佳非必需消費品ETF
接收《強生日報》的新聞和評級 -在下面輸入您的電子郵件地址,即可通過Marketbeat.com的免費每日電子郵件時事通訊接收強生及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧